<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; blockbuster</title>
	<atom:link href="http://www.tapanray.in/tag/blockbuster/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Drug Innovation and Pharma M&amp;As: A Recent Perspective</title>
		<link>http://www.tapanray.in/drug-innovation-and-pharma-mas-a-recent-perspective/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=drug-innovation-and-pharma-mas-a-recent-perspective</link>
		<comments>http://www.tapanray.in/drug-innovation-and-pharma-mas-a-recent-perspective/#comments</comments>
		<pubDate>Mon, 04 Jun 2018 00:00:46 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[acquisition]]></category>
		<category><![CDATA[blockbuster]]></category>
		<category><![CDATA[CEO]]></category>
		<category><![CDATA[critical]]></category>
		<category><![CDATA[deal]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[hefty]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[M&A]]></category>
		<category><![CDATA[merger]]></category>
		<category><![CDATA[objectives]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8949</guid>
		<description><![CDATA[The 21st CEO Survey 2018 of PwC highlights a curious contradiction. This is based on what the Global Pharma Chief Executive Officers (CEOs) had articulated regarding their business outlook for 2018 and beyond. The report says: Despite highly publicized hand &#8230; <a href="http://www.tapanray.in/drug-innovation-and-pharma-mas-a-recent-perspective/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/drug-innovation-and-pharma-mas-a-recent-perspective/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Global New Product Launches: Recent Success Trend Unflattering?</title>
		<link>http://www.tapanray.in/global-new-product-launches-recent-success-trend-unflattering/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=global-new-product-launches-recent-success-trend-unflattering</link>
		<comments>http://www.tapanray.in/global-new-product-launches-recent-success-trend-unflattering/#comments</comments>
		<pubDate>Mon, 24 Mar 2014 00:00:19 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[10]]></category>
		<category><![CDATA[2006]]></category>
		<category><![CDATA[2007]]></category>
		<category><![CDATA[big]]></category>
		<category><![CDATA[blockbuster]]></category>
		<category><![CDATA[FirstWord]]></category>
		<category><![CDATA[Gilead]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Januvia]]></category>
		<category><![CDATA[launches]]></category>
		<category><![CDATA[McKinsey]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[NME]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Product]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Sovaldi]]></category>
		<category><![CDATA[success]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[trend]]></category>
		<category><![CDATA[unflattering]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5132</guid>
		<description><![CDATA[New products are the lifeblood for any company, including the pharmaceutical players. Business performance and sustainable growth of the pharmaceutical industry, as a whole depend on quality of R&#38;D output in terms of &#8216;New Molecules&#8217;, followed by successful development and &#8230; <a href="http://www.tapanray.in/global-new-product-launches-recent-success-trend-unflattering/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/global-new-product-launches-recent-success-trend-unflattering/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma Horizon: Cloud, Rainbow And Smear</title>
		<link>http://www.tapanray.in/pharma-horizon-cloud-rainbow-and-smear/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-horizon-cloud-rainbow-and-smear</link>
		<comments>http://www.tapanray.in/pharma-horizon-cloud-rainbow-and-smear/#comments</comments>
		<pubDate>Mon, 09 Dec 2013 00:00:33 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[10]]></category>
		<category><![CDATA[ANDA]]></category>
		<category><![CDATA[Biocon]]></category>
		<category><![CDATA[biologics]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[blockbuster]]></category>
		<category><![CDATA[breast]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[cloudy]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[expiry]]></category>
		<category><![CDATA[Growing]]></category>
		<category><![CDATA[Herceptin]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[monster]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[rainbow]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[sky]]></category>
		<category><![CDATA[Sun Pharma]]></category>
		<category><![CDATA[taint]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[top]]></category>
		<category><![CDATA[total]]></category>
		<category><![CDATA[Trastuzumab]]></category>
		<category><![CDATA[UKMHRA]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[VUCA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=4400</guid>
		<description><![CDATA[Some recent papers contemplated that the patent cliff for blockbuster drugs has already reached the zenith and early signs of recovery should be visible from 2013 onwards. However, from analysis of the currently available data, contrary to the above belief, I reckon, the downtrend &#8230; <a href="http://www.tapanray.in/pharma-horizon-cloud-rainbow-and-smear/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-horizon-cloud-rainbow-and-smear/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Balancing IPR with Public Health Interest: Brickbats, Power Play and Bouquets</title>
		<link>http://www.tapanray.in/balancing-ipr-with-public-health-interest-brickbats-power-play-and-bouquets/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=balancing-ipr-with-public-health-interest-brickbats-power-play-and-bouquets</link>
		<comments>http://www.tapanray.in/balancing-ipr-with-public-health-interest-brickbats-power-play-and-bouquets/#comments</comments>
		<pubDate>Mon, 01 Jul 2013 00:00:39 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[America]]></category>
		<category><![CDATA[Argentina]]></category>
		<category><![CDATA[Balancing]]></category>
		<category><![CDATA[blockbuster]]></category>
		<category><![CDATA[bouquets]]></category>
		<category><![CDATA[Brazil]]></category>
		<category><![CDATA[brickbats]]></category>
		<category><![CDATA[Canada]]></category>
		<category><![CDATA[Carlos]]></category>
		<category><![CDATA[Columbia]]></category>
		<category><![CDATA[Correa]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[debate]]></category>
		<category><![CDATA[discovery]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[efficacy]]></category>
		<category><![CDATA[European]]></category>
		<category><![CDATA[ever greening]]></category>
		<category><![CDATA[expenditure]]></category>
		<category><![CDATA[Glivec]]></category>
		<category><![CDATA[good]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[incremental]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[interest]]></category>
		<category><![CDATA[inventive]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[Judgment]]></category>
		<category><![CDATA[Leash]]></category>
		<category><![CDATA[Leashing]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Mashelkar]]></category>
		<category><![CDATA[NCE]]></category>
		<category><![CDATA[organization]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[patentability]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[power play]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[raging]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reasonably]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[Revised]]></category>
		<category><![CDATA[Section(3d)]]></category>
		<category><![CDATA[Section2(ja)]]></category>
		<category><![CDATA[South Africa]]></category>
		<category><![CDATA[states]]></category>
		<category><![CDATA[step]]></category>
		<category><![CDATA[study]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[therapeutic]]></category>
		<category><![CDATA[TRIPS]]></category>
		<category><![CDATA[Union]]></category>
		<category><![CDATA[United]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USIBC]]></category>
		<category><![CDATA[wasteful]]></category>
		<category><![CDATA[World]]></category>
		<category><![CDATA[WOW]]></category>
		<category><![CDATA[WTO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2691</guid>
		<description><![CDATA[It is now a widely accepted dictum that Intellectual Property Rights (IPR), especially pharma patents, help fostering innovation and is critical in meeting unmet needs of the patients. However, the moot question still remains, what type pharmaceutical invention, should deserve &#8230; <a href="http://www.tapanray.in/balancing-ipr-with-public-health-interest-brickbats-power-play-and-bouquets/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/balancing-ipr-with-public-health-interest-brickbats-power-play-and-bouquets/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The Game Changer: Effective transition from ‘blockbuster’ to an integrated ‘niche buster’ plus &#8216;generic drugs&#8217; business model</title>
		<link>http://www.tapanray.in/the-game-changer-effective-transition-from-blockbuster-to-an-integrated-niche-buster-plus-generic-drugs-business-model/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-game-changer-effective-transition-from-blockbuster-to-an-integrated-niche-buster-plus-generic-drugs-business-model</link>
		<comments>http://www.tapanray.in/the-game-changer-effective-transition-from-blockbuster-to-an-integrated-niche-buster-plus-generic-drugs-business-model/#comments</comments>
		<pubDate>Sun, 20 Nov 2011 07:58:47 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[an]]></category>
		<category><![CDATA[blockbuster]]></category>
		<category><![CDATA[buster]]></category>
		<category><![CDATA[Changer]]></category>
		<category><![CDATA[drugs. business]]></category>
		<category><![CDATA[effective]]></category>
		<category><![CDATA[From]]></category>
		<category><![CDATA[Game]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[integrated]]></category>
		<category><![CDATA[model]]></category>
		<category><![CDATA[niche]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[plus]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[to]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=172</guid>
		<description><![CDATA[Since quite some time global pharmaceutical majors have been operating within the confines of high risk &#8211; high reward R&#38;D based business model with blockbuster drugs (annual sales of over US$ 1 billion). Blockbuster brands, mostly in the chronic-care segments &#8230; <a href="http://www.tapanray.in/the-game-changer-effective-transition-from-blockbuster-to-an-integrated-niche-buster-plus-generic-drugs-business-model/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-game-changer-effective-transition-from-blockbuster-to-an-integrated-niche-buster-plus-generic-drugs-business-model/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
